Nike to report Q2 earnings amid weak DTC trends, mixed sentiment

Nike will report fiscal Q2 results on Dec. 18 with UBS reiterating a Neutral rating and $71 price target and expecting a muted market reaction; consensus calls for revenue down ~1.7% to $12.15bn and EPS falling to $0.37 from $0.78. UBS flags decelerating DTC trends in North America and Europe, continued pressure in China and an overall “lackluster” global sales momentum, characterizing the recovery as slower and non-linear, and expects Q3 sales to be down low single digits with implied EPS of $0.20–$0.40 (below the $0.47 sell-side consensus) and no FY26 guidance. With options pricing a near 9% move (UBS sees nearer-term volatility closer to Nike’s ~6% historical level), sentiment has soured—shares are down ~14% over three months and the stock is showing a short‑crowded profile—so investors will be focused on any signs of sequential improvement that could meaningfully alter the outlook.

Analysis

Nike will report fiscal Q2 results on December 18; UBS has reiterated a Neutral rating with a $71 price target and expects a muted market reaction. Consensus forecasts call for revenue to decline 1.7% to $12.15 billion and EPS to drop from $0.78 to $0.37, setting a low bar for the print and near-term guidance.

UBS field checks describe “lackluster” global sales through November with decelerating direct-to-consumer (DTC) trends in North America and Europe, continued pressure in China, and an average 8% decline in Google search growth in Q2. UBS projects Q3 sales down low single digits and implied EPS of $0.20–$0.40 versus a sell-side consensus of $0.47, and does not expect formal FY26 guidance to be issued.

Market positioning is cautious: options markets price a ~9% move around earnings while UBS expects volatility nearer its historical ~6%, sentiment has turned moderately negative, shares are down roughly 14% over three months and UBS’s quant data flags a short-crowded profile. Investors will therefore focus on whether management can explicitly guide to sequential sales improvement into fiscal Q4; absent clear directional commentary the recovery looks slower and non-linear, increasing execution risk into the print.

Key Decisions for Investors

• Maintain a neutral or modestly underweight stance into the Q2 print given consensus revenue and EPS downside and UBS’s expectation of continued softness, avoid adding size ahead of clearer sequential recovery signals
• If management provides explicit, credible directional commentary and Q3 indications of sequential improvement toward Q4, consider adding exposure incrementally up to levels consistent with UBS’s $71 target, otherwise wait for a demonstrable inflection
• Monitor DTC metrics in North America and Europe, China sales trends and Nike’s Google search momentum as primary leading indicators that would change the thesis, and treat Q3 implied EPS guidance as a key catalyst
• Given options imply a ~9% move versus expected historical volatility nearer 6% and the stock’s short-crowded profile, use event-sized hedges such as protective puts or collars or consider selling premium selectively if risk tolerance and sizing allow